{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T07:53:35Z","timestamp":1790150015912,"version":"4.0.1"},"reference-count":65,"publisher":"Wiley","issue":"8","license":[{"start":{"date-parts":[[2026,7,29]],"date-time":"2026-07-29T00:00:00Z","timestamp":1785283200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"},{"start":{"date-parts":[[2026,7,29]],"date-time":"2026-07-29T00:00:00Z","timestamp":1785283200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"funder":[{"DOI":"10.13039\/100004917","name":"Cancer Prevention and Research Institute of Texas","doi-asserted-by":"publisher","award":["RP210130"],"award-info":[{"award-number":["RP210130"]}],"id":[{"id":"10.13039\/100004917","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Cancer Medicine"],"published-print":{"date-parts":[[2026,8]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Active surveillance strategies have evolved to incorporate new technologies, such as MRI. However, trends in the adoption of this technology within the first year after cancer diagnosis as part of the initial active surveillance activity remain unclear.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Using SEER\u2010Medicare data, this cross\u2010sectional study examined trends in the use of various active surveillance strategies, including MRI associated biopsy, within the first year of cancer diagnosis among men diagnosed with localized prostate cancer between 2010\u20132011 and 2018\u20132019. Patients were stratified by Gleason score, age, and race\/ethnicity.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Among patients without active treatment in the first year after localized prostate cancer diagnosis, the unadjusted proportion undergoing MRI associated biopsy as an active surveillance strategy increased from 0.8% in 2010\u20132011 to 3.16% in 2018\u20132019 for GS \u2264\u20096, and from 0.7% to 4.69% over the same period for GS \u2265\u20097. Patients aged 66\u201374 had consistently higher probabilities of undergoing MRI associated biopsy than patients aged 75+, and non\u2010Hispanic White patients had consistently higher probabilities of undergoing MRI associated biopsy than non\u2010Hispanic Black.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>The use of new active surveillance strategies, such as MRI associated biopsy, were low in overall use but increased over time from 2010\u20132011 to 2018\u20132019, with notable differences across patient subgroups defined by age and race\/ethnicity.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1002\/cam4.72155","type":"journal-article","created":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T05:39:00Z","timestamp":1785389940000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Trends in the Adoption of\n                    <scp>MRI<\/scp>\n                    Associated Biopsy for Active Surveillance Within the First Year After Localized Prostate Cancer Diagnosis: A\n                    <scp>SEER<\/scp>\n                    \u2010Medicare Cohort Study"],"prefix":"10.1002","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5246-0290","authenticated-orcid":false,"given":"Yu","family":"Liu","sequence":"first","affiliation":[{"name":"Department of Public Health Sam Houston State University  Huntsville Texas USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6126-6465","authenticated-orcid":false,"given":"Efstathia","family":"Polychronopoulou","sequence":"additional","affiliation":[{"name":"Department of Biostatistics &amp; Data Science The University of Texas Medical Branch  Galveston Texas USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jamaal","family":"Jackson","sequence":"additional","affiliation":[{"name":"Division of Urology The University of Texas Medical Branch  Galveston Texas USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen","family":"Williams","sequence":"additional","affiliation":[{"name":"Division of Urology The University of Texas Medical Branch  Galveston Texas USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1927-0927","authenticated-orcid":false,"given":"Yong\u2010fang","family":"Kuo","sequence":"additional","affiliation":[{"name":"Department of Biostatistics &amp; Data Science The University of Texas Medical Branch  Galveston Texas USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2026,7,29]]},"reference":[{"key":"e_1_2_14_2_1","volume-title":"Prostate Cancer Statistics CDC.gov: CDC","author":"CDC","year":"2025"},{"key":"e_1_2_14_3_1","doi-asserted-by":"publisher","DOI":"10.3322\/caac.70043"},{"key":"e_1_2_14_4_1","volume-title":"Cancer Stat Facts: Prostate Cancer: Cancer.Gov","author":"SEER","year":"2026"},{"key":"e_1_2_14_5_1","doi-asserted-by":"publisher","DOI":"10.6004\/jnccn.2010.0012"},{"key":"e_1_2_14_6_1","doi-asserted-by":"publisher","DOI":"10.5489\/cuaj.2806"},{"key":"e_1_2_14_7_1","doi-asserted-by":"publisher","DOI":"10.3390\/jpm13040629"},{"key":"e_1_2_14_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.urolonc.2020.11.024"},{"key":"e_1_2_14_9_1","doi-asserted-by":"publisher","DOI":"10.1002\/pros.23496"},{"key":"e_1_2_14_10_1","doi-asserted-by":"publisher","DOI":"10.1177\/00469580251342466"},{"key":"e_1_2_14_11_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2023.1439"},{"key":"e_1_2_14_12_1","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21333"},{"key":"e_1_2_14_13_1","doi-asserted-by":"publisher","DOI":"10.3390\/cancers18050842"},{"key":"e_1_2_14_14_1","doi-asserted-by":"publisher","DOI":"10.1177\/15353508241245265"},{"key":"e_1_2_14_15_1","doi-asserted-by":"publisher","DOI":"10.1177\/15353508241261473"},{"key":"e_1_2_14_16_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.urolonc.2016.03.001"},{"key":"e_1_2_14_17_1","doi-asserted-by":"publisher","DOI":"10.5694\/mja2.51722"},{"key":"e_1_2_14_18_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41391-022-00543-4"},{"key":"e_1_2_14_19_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.33518"},{"key":"e_1_2_14_20_1","doi-asserted-by":"publisher","DOI":"10.2214\/AJR.20.23462"},{"key":"e_1_2_14_21_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(16)32401-1"},{"key":"e_1_2_14_22_1","doi-asserted-by":"publisher","DOI":"10.6004\/jnccn.2014.0072"},{"key":"e_1_2_14_23_1","doi-asserted-by":"publisher","DOI":"10.6004\/jnccn.2016.0004"},{"key":"e_1_2_14_24_1","volume-title":"NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines). NCCN.org","author":"NCCN","year":"2016"},{"issue":"5","key":"e_1_2_14_25_1","first-page":"583","article-title":"NCCN Guidelines Updates: Management of Prostate Cancer","volume":"17","author":"Mohler J. L.","year":"2019","journal-title":"Journal of the National Comprehensive Cancer NetworkJournal of the National Comprehensive Cancer Network"},{"key":"e_1_2_14_26_1","doi-asserted-by":"publisher","DOI":"10.6004\/jnccn.2025.0052"},{"key":"e_1_2_14_27_1","unstructured":"\u201cProstate Cancer Version 3.2026 NCCN Clinical Practice Guidelines in Oncology \u201d(2026) https:\/\/www.nccn.org\/patients\/guidelines\/content\/PDF\/prostate\u2010early\u2010patient.pdf."},{"issue":"1","key":"e_1_2_14_28_1","first-page":"10","article-title":"Clinically Localized Prostate Cancer: AUA\/ASTRO Guideline, Part I: Introduction, Risk Assessment, Staging, and Risk\u2010Based Management","volume":"208","author":"Eastham J. A.","year":"2022","journal-title":"Practice Guideline"},{"key":"e_1_2_14_29_1","doi-asserted-by":"publisher","DOI":"10.1097\/JU.0000000000000617"},{"key":"e_1_2_14_30_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.juro.2017.04.101"},{"key":"e_1_2_14_31_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2020.09.042"},{"key":"e_1_2_14_32_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00330-011-2377-y"},{"key":"e_1_2_14_33_1","doi-asserted-by":"publisher","DOI":"10.5152\/tud.2020.20403"},{"key":"e_1_2_14_34_1","doi-asserted-by":"publisher","DOI":"10.12659\/MSM.920252"},{"issue":"2","key":"e_1_2_14_35_1","first-page":"77","article-title":"Active Surveillance of Prostate Cancer: Current State of Practice and Utility of Multiparametric Magnetic Resonance Imaging","volume":"19","author":"Alam R.","year":"2017","journal-title":"Reviews in Urology"},{"key":"e_1_2_14_36_1","doi-asserted-by":"publisher","DOI":"10.4274\/balkanmedj.2017.0708"},{"key":"e_1_2_14_37_1","doi-asserted-by":"publisher","DOI":"10.1148\/rycan.240091"},{"key":"e_1_2_14_38_1","doi-asserted-by":"publisher","DOI":"10.1148\/radiol.242164"},{"key":"e_1_2_14_39_1","doi-asserted-by":"publisher","DOI":"10.1097\/01.mlr.0000156849.15166.ec"},{"key":"e_1_2_14_40_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11934-017-0724-5"},{"key":"e_1_2_14_41_1","doi-asserted-by":"publisher","DOI":"10.1093\/jncimonographs\/lgs035"},{"key":"e_1_2_14_42_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.34433"},{"key":"e_1_2_14_43_1","doi-asserted-by":"publisher","DOI":"10.1097\/CCO.0b013e32835eb5d1"},{"key":"e_1_2_14_44_1","doi-asserted-by":"publisher","DOI":"10.1002\/pros.21314"},{"key":"e_1_2_14_45_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.19.01963"},{"key":"e_1_2_14_46_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jval.2023.06.003"},{"key":"e_1_2_14_47_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1475-6773.2009.01004.x"},{"key":"e_1_2_14_48_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2021.9937"},{"key":"e_1_2_14_49_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.euf.2019.04.008"},{"key":"e_1_2_14_50_1","unstructured":"NCI \u201cSEER\u2010Medicare Linked Data Resource \u201daccessed July 20 2025 https:\/\/healthcaredelivery.cancer.gov\/seermedicare\/."},{"key":"e_1_2_14_51_1","unstructured":"\u201cSEER\u2010Medicare: Brief Description of the SEER\u2010Medicare Database \u201d(2018) accessed January 24 2019 https:\/\/healthcaredelivery.cancer.gov\/seermedicare\/overview\/."},{"key":"e_1_2_14_52_1","volume-title":"Prostate Cancer. NCCN Guidelines Version 2.2021","author":"National Comprehensive Cancer Network","year":"2021"},{"key":"e_1_2_14_53_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2214122"},{"key":"e_1_2_14_54_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12913-016-1886-4"},{"key":"e_1_2_14_55_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41391-021-00393-6"},{"key":"e_1_2_14_56_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0895-4356(00)00256-0"},{"key":"e_1_2_14_57_1","volume-title":"The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) Statement: Guidelines for Reporting Observational Studies","author":"Equator\u2010network","year":"2022"},{"key":"e_1_2_14_58_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.juro.2016.02.2963"},{"key":"e_1_2_14_59_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41391-022-00580-z"},{"key":"e_1_2_14_60_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.juro.2011.12.082"},{"key":"e_1_2_14_61_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.urology.2014.08.014"},{"key":"e_1_2_14_62_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.urology.2013.09.038"},{"key":"e_1_2_14_63_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1801993"},{"key":"e_1_2_14_64_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2018.11.023"},{"key":"e_1_2_14_65_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2016.06.011"},{"key":"e_1_2_14_66_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2024.03.014"}],"container-title":["Cancer Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/cam4.72155","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/cam4.72155","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/cam4.72155","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T12:26:26Z","timestamp":1787660786000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/cam4.72155"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,29]]},"references-count":65,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2026,8]]}},"alternative-id":["10.1002\/cam4.72155"],"URL":"https:\/\/doi.org\/10.1002\/cam4.72155","archive":["Portico"],"relation":{},"ISSN":["2045-7634","2045-7634"],"issn-type":[{"value":"2045-7634","type":"print"},{"value":"2045-7634","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,29]]},"assertion":[{"value":"2026-05-26","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-07-23","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-07-29","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e72155"}}